Trial Profile
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 27 Sep 2018 Planned End Date changed from 1 May 2017 to 1 May 2019.
- 15 Sep 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.